trending Market Intelligence /marketintelligence/en/news-insights/trending/4pbyye2j-44bolws_ldcxw2 content esgSubNav
In This List

SELLAS therapy secures US FDA orphan drug status to treat multiple myeloma

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


SELLAS therapy secures US FDA orphan drug status to treat multiple myeloma

SELLAS Life Sciences Group Inc. said the U.S. Food and Drug Administration granted orphan drug designation to its medicine galinpepimut-S to treat multiple myeloma, a type of cancer that forms in the plasma cells.

The New York-based biopharmaceutical company said both the U.S. FDA and the European Medicines Agency have already granted orphan drug status for galinpepimut-S to treat acute myeloid leukemia, a type of blood cancer, and malignant pleural mesothelioma, a type of lung cancer.

Orphan drug designation may provide certain benefits, including a seven-year period of market exclusivity if the drug is approved.